PRESS RELEASES

PRESS RELEASES

March 13, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 13, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin’s proprietary demineralization technology, OsteoSTX are flexible cortical DBM
March 10, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Mar. 10, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, announced the closing of an additional $4 million financing from OrbiMed.
February 4, 2014
BELGRADE, Mont. --(BUSINESS WIRE)--Feb. 4, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CEO, Dan Goldberger , and CFO, John Gandolfo , will present at the
January 23, 2014
Fourth Quarter Revenue in the range of $8.15 million to $8.28 million , an increase of 4% sequentially, and 1.5% over the same period last year. Fourth Quarter Biologics Revenue in the range of $8.02 million to $8.07 million , up 5.0% sequentially and 4.5% over the same period last year.